Related Experiment Video
Updated: Aug 7, 2026
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
[In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]
A J Carrillo Muñoz1, C Tur, D Estivill
1Laboratori de Microbiología, Institut MUnicipal d'Investigació Médica (IMIM), Barcelona, Spain. ajcm.acia@bcn.servicom.es
Abstract:
An in vitro susceptibility testing of 181 strains of six species of Candida and 21 strains of Cryptococcus neoformans was carried out in order to investigate the resistance to new antifungal drugs. We have studied clinical isolates from 200 different patients of Hospital del Mar (Barcelona) and Hospital La Inmaculada (Almería). An agar diffusion method (NeoSensitabs, Rosco, Taastrup, Denmark), was employed with fluconazole, itraconazole, and reference drugs amphotericin B, flucytosine, tioconazole and ketoconazole. A high level of susceptibility was found for amphotericin B in C. neoformans strains while 19% of them were resistant to flucytosine. All the strains of C. neoformans and Candida guilliermondii were susceptible to the new azoles derivatives and also Candida parapsilosis and Candida albicans had a great susceptibility to this antifungals. A greater level of resistance was found for Candida krusei, Candida tropicalis and Candida glabrata to fluconazole, itraconazole and ketoconazole, but resistance to fluconazole and itraconazole is not always linked because ten resistant strains for fluconazole were susceptible to itraconazole, and two other resistant to itraconazole were susceptible to fluconazole.
Insights
This study investigated antifungal drug resistance in Candida and Cryptococcus neoformans clinical isolates. While most strains showed susceptibility to new azoles, some Candida species exhibited resistance, highlighting the need for ongoing monitoring.
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
- Clinical Microbiology
Context:
- Emerging resistance to antifungal drugs poses a significant threat to treating invasive fungal infections.
- Clinical isolates from diverse patient populations are crucial for understanding real-world resistance patterns.
- The study focuses on common fungal pathogens, Candida and Cryptococcus neoformans.
Purpose:
- To determine the in vitro susceptibility of Candida and Cryptococcus neoformans to new antifungal agents.
- To investigate the prevalence of resistance to fluconazole, itraconazole, amphotericin B, and flucytosine.
- To compare the efficacy of different antifungal drugs against various fungal species.
Summary:
- In vitro susceptibility testing was performed on 181 Candida strains and 21 Cryptococcus neoformans strains using an agar diffusion method.
- Amphotericin B demonstrated high susceptibility against C. neoformans, while 19% of these strains were resistant to flucytosine.
- C. neoformans, Candida guilliermondii, Candida parapsilosis, and Candida albicans showed susceptibility to new azoles; however, Candida krusei, Candida tropicalis, and Candida glabrata displayed greater resistance.
Impact:
- Findings provide essential data on antifungal drug resistance profiles for guiding clinical treatment decisions.
- Highlights the need for susceptibility testing, especially for less common Candida species.
- Contributes to the understanding of antifungal drug mechanisms and the development of new therapeutic strategies.
More Related Videos
Related Concept Videos
01:20Candidiasis
01:27Cryptococcal Meningitis